ASCLETIS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.36 HKD | -2.86% |
|
-2.86% | -6.85% |
| Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Evolution of the average Target Price on Ascletis Pharma Inc.
Price target over the last 5 years
History of analyst recommendation changes
722609a0c8609a46449c61be59cb9d20.v6lDYDpuIIIsyfhxucCOHVr1PNLun4TVR2XnC9ytjMw.xZEoLlYva8BG-KAXyaLPLzaqcOCY7vWNcQauRoT0wa3-5gYKCz1utnjxuQ~da0b9091cb15231df42e1f4171a58d3c
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.292
CNY
Average target price
2.752
CNY
Spread / Average Target
+113.04%
High Price Target
3.513
CNY
Spread / Highest target
+171.96%
Low Price Target
1.991
CNY
Spread / Lowest Target
+54.13%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 1672 Stock
- Consensus Ascletis Pharma Inc.